The dosage and administration of SANDOSTATIN LAR needs to be customized by the doctor according to the patient's specific situation. Generally, SANDOSTATIN LAR needs to be injected at the prescribed dose and frequency, and the dose needs to be gradually increased to achieve the best therapeutic effect.

Sandostatin LAR Dosage and Administration

1. Instructions

(1)Sandostatin LAR should be administered by trained medical personnel, and it is important to strictly follow the instructions on the package. Sandostatin LAR needs to be used immediately after mixing.

(2) Do not inject the diluent directly without preparing the suspension.

(3) The recommended needle size for Sanlon is a 1½” 19-gauge safety injection needle (provided in the drug package). For patients with greater skin-to-muscle depth, a 2-inch 19-gauge needle (not provided) can be used.

(4) Sanlon should be injected into the gluteal muscle every 4 weeks. It is not recommended to administer Sanlon more than 4 weeks apart.

(5) The injection site should be rotated on a planned basis to avoid irritation. Injections into the deltoid muscle should be avoided as there is significant discomfort at the injection site when injecting into this area.

(6) It should not be injected intravenously or subcutaneously.

2. Acromegaly

(1) Patients not currently receiving octreotide acetate

① Patients not currently receiving octreotide acetate Patients treated with octreotide should start with subcutaneous SANDOSTATIN at an initial dose of 50mcg three times daily, which can be gradually increased. Most patients require a dose of 100mcg to 200mcg three times daily to achieve maximum effect, but some patients require doses up to 500mcg three times daily.

② Patients should maintain subcutaneous SANDOSTATIN for at least 2 weeks to determine tolerance to octreotide acetate. Patients who are considered to be responsive to and able to tolerate the drug based on growth hormone and insulin-like growth factor 1 levels can be switched to Sanlostatin according to the following dosage regimen.

(2) Currently Patients currently receiving SANDOSTATIN injections

Patients currently receiving SANDOSTATIN injections can directly switch to Sandostatin at a dose of 20 mg, injected intramuscularly into the gluteal muscle every 4 weeks for 3 months. After 3 months, the dose can be adjusted as follows:

① Growth hormone ≤ 2.5 ng/mL, normal insulin-like growth factor 1, and clinical symptoms are controlled: maintain the Sandostatin dose at 20 mg every 4 weeks.

② Growth hormone > 2.5 ng/mL, elevated insulin-like growth factor 1, and/or uncontrolled clinical symptoms, increase the Sandostatin dose to 30 mg every 4 weeks.

③ Growth hormone ≤ 1 ng/ mL, normal insulin-like growth factor 1, and clinical symptoms are under control, reduce the dose of Sanlong to 10 mg every 4 weeks.

④ If growth hormone, insulin-like growth factor 1 or symptoms cannot be adequately controlled at a dose of 30 mg, the dose can be increased to 40 mg every 4 weeks. Doses exceeding 40 mg are not recommended.

⑤ For patients undergoing pituitary radiotherapy, the drug should be discontinued for about 8 weeks each year to assess the activity of the disease. If growth hormone or insulin-like growth factor levels increase and signs and symptoms recur, treatment with Sanlong can be resumed.

For more information on usage and dosage for different populations and indications, consult a doctor for individualized medication adjustments.